BioLife Solutions insider sells 358 shares under 10b5-1 plan

BioLife Solutions Inc. reported an insider stock sale by its Chief Marketing Officer.

Rhea-AI Filing Summary

BioLife Solutions Inc. reported an insider stock sale by its Chief Marketing Officer. On 12/09/2025, the officer sold 358 shares of common stock at a price of $25.13 per share. After this transaction, the officer beneficially owned 132,908 shares in a direct capacity.

The sale was made under a Rule 10b5-1(c) trading plan that the reporting person adopted effective 03-08-2024 to cover tax withholding obligations tied to the vesting of restricted stock. This indicates the transaction was pre-arranged for tax purposes rather than a discretionary open-market sale.

Insider Trade Summary

Net Seller: 358 shares

Net Sell 1 txn

Insider Berard Todd

Role Chief Marketing Officer

Sold 358 shs ($9K)

Type	Security	Shares	Price	Value
Sale	Common Stock	358	$25.13	$9K

Holdings After Transaction: Common Stock — 132,908 shares (Direct)

Footnotes (1)

1. F1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioLife Solutions (BLFS) report in this Form 4?

The filing reports that the Chief Marketing Officer of BioLife Solutions Inc. sold 358 shares of common stock on 12/09/2025 in a direct transaction.

At what price were the BioLife Solutions (BLFS) shares sold in this insider transaction?

The officer sold 358 shares of BioLife Solutions common stock at a price of $25.13 per share.

How many BioLife Solutions (BLFS) shares does the insider own after this sale?

Following the reported sale, the Chief Marketing Officer beneficially owned 132,908 shares of BioLife Solutions common stock, held directly.

Was the BioLife Solutions (BLFS) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was made under a Rule 10b5-1(c) trading plan adopted by the reporting person, effective 03-08-2024.

Why did the BioLife Solutions (BLFS) insider sell shares according to the filing?

The explanation notes that the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock held by the reporting person.

What is the role of the reporting person in BioLife Solutions (BLFS)?

The reporting person is identified as an officer of BioLife Solutions Inc., serving as the company’s Chief Marketing Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/17/2025 - 05:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berard Todd

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		S(1)		358	D	$25.13	132,908	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Todd Berard	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.